Bristol-Myers Squibb establishes collaborative Immuno-Oncology Rare Population Malignancy (I-O RPM) program in the U.S.

Bristol-Myers SquibbBristol-Myers Squibb Company (NYSE:BMY) has announced the establishment of the Immuno-Oncology Rare Population Malignancy (I-O RPM) program in the U.S. The I-O RPM program is a multi-institutional initiative with academic-based cancer centers focused on the clinical investigation of Immuno-Oncology therapeutics as potential treatment options for patients with high risk, poor prognostic cancers, defined as a rare population malignancy. A rare population malignancy is a subpopulation within a higher incident disease population (e.g. BRCA 1 and 2 breast cancer). These patients have aggressive disease with an increased potential for early metastasis to multiple sites and/or are initially refractory or subject to early recurrences with conventional cancer therapies.

As part of the I-O RPM program, Bristol-Myers Squibb, the Robert H. Lurie Comprehensive Cancer Center of Northwestern University (Lurie Cancer Center) and the Northwestern Medicine Developmental Therapeutics Institute (NMDTI) are pleased to announce that they have entered into a collaboration agreement. The Lurie Cancer Center and NMDTI will conduct a range of early phase clinical studies and Bristol-Myers Squibb will fund positions within the NMDTI Developmental Therapeutics Fellowship program.

"Complementing our broad research and development programs through innovative collaborations with partners such as the Lurie Cancer Center and NMDTI has been a fundamental component to our commitment to leading advances in Immuno-Oncology," said Laura Bessen, M.D., head of U.S. Medical, Bristol-Myers Squibb. "Cooperation between industry and research partners of this caliber offers a tremendous opportunity to further strengthen our scientific and clinical understanding of the role immunotherapies can play in the treatment of a broad range of cancers."

"Immunotherapy is rapidly evolving and has an enormous promise for cancer patients. This collaborative effort with Bristol-Myers Squibb will further strengthen our efforts to develop innovative new therapies against a wide variety of malignancies," said Leonidas C. Platanias, M.D., Ph.D., director of the Lurie Cancer Center.

"The Rare Population Malignancy Program is a very timely and important initiative. The ability to rapidly investigate the clinical utility of Bristol-Myers Squibb's Immuno-Oncology agents, as single agents or in combinations, including with therapies from other sources, is a powerful accelerant to our programs. The focus on malignancies that are otherwise relatively under-investigated in therapeutic terms is particularly important and satisfying for all involved in this collaboration," said Francis J. Giles, M.D., director of the NMDTI and deputy director of the Lurie Cancer Center.

Immuno-Oncology is an innovative approach to cancer research and treatment that is designed to harness the body's own immune system to fight cancer. The I-O RPM program will focus on significant areas of high unmet need marked by poor outcomes among patients with these cancers. Existing clinical research, including studies being conducted by the Lurie Cancer Center and NMDTI, provide a strong rationale for further research into the potential of immunotherapies for these cancers.

About Bristol Myers Squibb
The I-O RPM builds on Bristol-Myers Squibb's formation in 2012 of the International Immuno-Oncology Network (II-ON). II-ON is a global collaboration between Bristol-Myers Squibb and academia focused on facilitating the translation of scientific research findings into clinical trials and, eventually, clinical practice.

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

About the Robert H. Lurie Comprehensive Cancer Center of Northwestern University
The Robert H. Lurie Comprehensive Cancer Center of Northwestern University is one of only 45 National Cancer Institute (NCI)-designated "Comprehensive" cancer centers in the nation. In addition, the Lurie Cancer Center is a founding member of the National Comprehensive Cancer Network (NCCN), an alliance of 25 of the world's leading cancer centers dedicated to improving the quality and effectiveness of care provided to patients with cancer and part of the Big Ten Cancer Research Consortium, a network of academic institutions working together on highly translational clinical trials using the expertise of Big Ten universities. The Lurie Cancer Center is affiliated with four leading teaching hospitals in Chicago — Northwestern Memorial Hospital, Ann & Robert H. Lurie Children's Hospital of Chicago, the Rehabilitation Institute of Chicago, and the Jesse Brown Veteran's Affairs Medical Center, treating more than 10,000 new patients with cancer each year. The Lurie Cancer Center receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA060553).

About the Northwestern Medicine Developmental Therapeutics Institute
The Northwestern Medicine Developmental Therapeutics Institute (NMDTI) provides infrastructure and expertise to accelerate the developmental therapeutics process. With dedicated patient care facilities, experienced physician-scientists, and specialized advanced practice providers, pharmacists, and allied staff, NMDTI brings a large external pipeline of investigational agents to our patients while accelerating the development of Northwestern University's internal pipeline of novel therapies. The NMDTI Developmental Therapeutics Fellowship, supported by the Woman's Board of Northwestern Memorial Hospital, focuses on nurturing physician scientists whose career is dedicated to the development of novel approaches to curing cancer.

Most Popular Now

Pre-clinical success for a universal flu vaccine o…

Researchers from the University of Oxford's Department of Zoology have demonstrated pre-clinical success for a universal flu vaccine in a new paper published in Nature Co...

Imfinzi is the first immunotherapy to demonstrate …

AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of Imfinzi durin...

Sandoz Healthcare Access Challenge #SandozHACk ret…

Sandoz, the Novartis generics and biosimilars division, today announces the launch of the second Sandoz Healthcare Access Challenge (HACk). The #SandozHACk is a global co...

Global survey reveals that physicians need more in…

Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make inf...

In clinical trials, new antibody therapy controls …

Thanks to improvements in antiretroviral therapy, HIV is now a manageable condition. Yet even the best drugs do not entirely eliminate the virus, which latently lingers i...

The Nobel Prize in Physiology or Medicine 2018 was…

Cancer kills millions of people every year and is one of humanity's greatest health challenges. By stimulating the inherent ability of our immune system to attack tumor c...

Novartis licenses three novel anti-infective progr…

Novartis announced today that it has entered into a licensing and equity agreement with Boston Pharmaceuticals for the development of three novel anti-infective drug cand...

Pfizer to award more than $3 million in grants to …

Pfizer Inc. today announced the recipients of the Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) Breast Cancer Research Awards. Four grants tota...

FDA approves first treatment for advanced form of …

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squam...

DNA islands effective as 'anti-bacterial drones'

Genomic "islands" that evolved from viruses can be converted into "drones" that disable Staphylococcus aureus, bacteria that are often resistant to antibiotics and pose a...

FDA awards 12 grants to fund new clinical trials t…

The U.S. Food and Drug Administration today announced that it has awarded 12 new clinical trial research grants totaling more than $18 million over the next four years to...

Addressing social and cultural drivers of type 2 d…

New research shows healthcare services and public health strategies aimed at reducing the burden of type 2 diabetes may prove ineffective, unless they address social and ...